Clin2
NCT06955988Possibly a fitRecruiting

Safety and early results of AST2303 for advanced lung cancer

Locally Advanced or Metastatic Non-small Cell Lung Cancer

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
120 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older
  • You must have advanced or metastatic non-small cell lung cancer confirmed by biopsy or cell sample
  • You must have at least one tumor that can be measured on scans and has not been treated locally
  • You must be willing to provide blood and/or tumor tissue for genetic testing
  • You must be in good overall health with normal bone marrow and organ function
  • You must be able to swallow pills normally

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07175220Recruiting· Phase 2
Study of SHR2554 tablets combined with other treatments for lung cancer

This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.

Guangzhou, Guangdong
NCT05482568Recruiting· Phase 1/Phase 2
Study drug SHR-A1811 with two lung cancer medicines

This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.

Shanghai, Shanghai Municipality
NCT06682780Recruiting· Phase 1/Phase 2
Testing LM-2417 for advanced solid tumors

This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.

Shanghai, Shanghai Municipality
NCT05956587Recruiting· Phase 2
Testing two study drugs for advanced lung cancer and other tumors

This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.

Chongqing, Chongqing Municipality
NCT06892548Recruiting· Phase 1/Phase 2
Combination therapy for advanced lung cancer

This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.

Phoenix, Arizona
NCT06245330Recruiting· Phase 1/Phase 2
Study of AST-001 for advanced solid tumors

This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.

Changchun, Jinlin

Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.